iShares Genomics Immunology and Healthcare ETF (IDNA)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
iShares Genomics Immunology and Healthcare ETF (IDNA) with AI Score 47/100 (Weak). The iShares Genomics Immunology and Healthcare ETF (IDNA) aims to track the investment results of an index focused on companies benefiting from advancements in genomics, immunology, and bioengineering. Market cap: 0, Sector: Financial services.
Last analyzed: Mar 16, 2026iShares Genomics Immunology and Healthcare ETF (IDNA) Financial Services Profile
iShares Genomics Immunology and Healthcare ETF (IDNA) offers investors targeted exposure to companies poised to benefit from long-term growth trends in genomics, immunology, and bioengineering. With a focus on both developed and emerging markets, IDNA provides a diversified investment vehicle for capitalizing on innovation within the healthcare sector, while exhibiting a beta of 1.35.
Investment Thesis
The iShares Genomics Immunology and Healthcare ETF (IDNA) presents an investment opportunity centered on the long-term growth potential of genomics, immunology, and bioengineering. The ETF's focus on companies in both developed and emerging markets allows investors to capitalize on global innovation trends within the healthcare sector. With a beta of 1.35, IDNA exhibits moderate volatility relative to the broader market. Key value drivers include the increasing demand for personalized medicine, the development of novel immunotherapies for cancer and other diseases, and the application of bioengineering technologies to address unmet medical needs. Upcoming catalysts include regulatory approvals for new therapies, advancements in genomic sequencing technologies, and increased investment in healthcare infrastructure in emerging markets. Potential risks include regulatory hurdles, clinical trial failures, and competitive pressures from established pharmaceutical companies.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.16 billion, indicating a relatively small-cap ETF.
- Beta of 1.35, suggesting higher volatility compared to the broader market.
- Exposure to both developed and emerging market companies in the genomics, immunology, and healthcare sectors.
- Focus on companies that could benefit from long-term growth and innovation in these fields.
- Managed by BlackRock, a leading global asset management firm.
Competitors & Peers
Strengths
- Exposure to high-growth sectors: genomics, immunology, and bioengineering.
- Diversified portfolio of companies in both developed and emerging markets.
- Managed by BlackRock, a leading global asset management firm.
- Focus on long-term growth trends in innovative healthcare fields.
Weaknesses
- Relatively small market capitalization, which may limit liquidity.
- Higher beta compared to the broader market, indicating greater volatility.
- Concentration in specific sectors, which may increase risk.
- Dependence on the performance of companies in the genomics, immunology, and healthcare sectors.
Catalysts
- Upcoming: Regulatory approvals for new therapies and medical devices.
- Ongoing: Advancements in genomic sequencing and data analytics.
- Ongoing: Increased investment in healthcare infrastructure in emerging markets.
- Ongoing: Growing demand for personalized medicine and innovative treatments.
Risks
- Potential: Clinical trial failures and setbacks in drug development.
- Potential: Regulatory hurdles and changes in government policies.
- Potential: Economic downturns impacting healthcare spending.
- Ongoing: Competitive pressures from established pharmaceutical companies.
- Ongoing: Market volatility and fluctuations in stock prices.
Growth Opportunities
- Personalized Medicine: The increasing adoption of personalized medicine, driven by advances in genomic sequencing and data analytics, presents a significant growth opportunity for companies in the genomics and healthcare sectors. The global personalized medicine market is projected to reach $2.4 trillion by 2030, growing at a CAGR of 11.2% from 2023. IDNA's exposure to companies involved in genomic sequencing, diagnostics, and targeted therapies positions it to benefit from this trend. Timeline: Ongoing.
- Immunotherapy Advancements: The development of novel immunotherapies for cancer and other diseases is revolutionizing the treatment landscape. The global immunotherapy market is expected to reach $250 billion by 2028, driven by the success of checkpoint inhibitors and CAR-T cell therapies. IDNA's holdings in companies developing and commercializing immunotherapies provide exposure to this high-growth area. Timeline: Ongoing.
- Bioengineering Innovation: Bioengineering technologies, such as gene editing and synthetic biology, are transforming healthcare and creating new opportunities for therapeutic interventions. The global bioengineering market is projected to reach $100 billion by 2027, driven by advancements in CRISPR-Cas9 technology and other gene editing tools. IDNA's exposure to companies involved in gene editing and synthetic biology positions it to capitalize on this emerging field. Timeline: Ongoing.
- Emerging Market Expansion: The increasing healthcare expenditures and growing middle class in emerging markets present a significant growth opportunity for companies in the genomics, immunology, and healthcare sectors. Countries like China and India are investing heavily in healthcare infrastructure and promoting the adoption of innovative therapies. IDNA's exposure to companies with operations in emerging markets allows investors to tap into this growth potential. Timeline: Ongoing.
- Aging Population: The global aging population is driving increased demand for healthcare services and products, particularly in areas such as age-related diseases and chronic conditions. The number of people aged 65 and over is projected to reach 1.6 billion by 2050. IDNA's focus on genomics, immunology, and healthcare aligns with the needs of an aging population, providing exposure to companies developing solutions for age-related health challenges. Timeline: Ongoing.
Opportunities
- Increasing adoption of personalized medicine.
- Advancements in immunotherapy and bioengineering technologies.
- Growing healthcare expenditures in emerging markets.
- Aging global population driving demand for healthcare services.
Threats
- Regulatory hurdles and clinical trial failures.
- Competitive pressures from established pharmaceutical companies.
- Economic downturns impacting healthcare spending.
- Changes in government policies affecting the healthcare industry.
Competitive Advantages
- Brand recognition and reputation of BlackRock, a leading global asset management firm.
- Diversified portfolio of companies in the genomics, immunology, and healthcare sectors.
- Exposure to both developed and emerging markets.
- Focus on long-term growth trends in innovative healthcare fields.
About IDNA
The iShares Genomics Immunology and Healthcare ETF (IDNA) is designed to provide investors with exposure to companies that are expected to benefit from the ongoing advancements and long-term growth in the fields of genomics, immunology, and bioengineering. Managed by BlackRock, a leading global asset management firm, IDNA seeks to replicate the investment results of an underlying index composed of equities from both developed and emerging markets. The ETF's holdings span a range of companies involved in various aspects of these innovative sectors, including biotechnology firms, pharmaceutical companies, and providers of healthcare services and equipment. IDNA's investment strategy focuses on identifying companies that are at the forefront of genomic research, developing novel immunotherapies, and pioneering bioengineering technologies. By investing in a diversified portfolio of companies within these fields, the ETF aims to capture the potential upside from breakthroughs and advancements that could transform healthcare and improve patient outcomes. The ETF's global reach allows investors to tap into growth opportunities in both established and emerging markets, providing a broader perspective on the evolving landscape of genomics, immunology, and healthcare. As of 2026, IDNA has a market capitalization of $0.16 billion.
What They Do
- Tracks the investment results of an index composed of developed and emerging market companies.
- Focuses on companies that could benefit from long-term growth and innovation in genomics.
- Targets companies involved in immunology research and development.
- Includes companies engaged in bioengineering technologies.
- Provides investors with exposure to the healthcare sector.
- Offers a diversified portfolio of companies within these innovative fields.
- Aims to capture the potential upside from breakthroughs and advancements in healthcare.
Business Model
- The ETF generates revenue through management fees charged to investors.
- The fund invests in a diversified portfolio of companies in the genomics, immunology, and healthcare sectors.
- The ETF seeks to replicate the investment results of an underlying index.
- The ETF's performance is driven by the growth and innovation of the companies it holds.
Industry Context
The asset management industry is characterized by increasing competition, evolving regulatory landscapes, and growing demand for specialized investment products. ETFs like IDNA cater to investors seeking targeted exposure to specific sectors or themes, such as genomics and immunology. The global healthcare market is experiencing rapid growth, driven by factors such as an aging population, rising healthcare expenditures, and technological advancements. IDNA's focus on genomics, immunology, and bioengineering aligns with the broader trend towards personalized medicine and innovative therapies. Competitors in the ETF space include firms offering similar thematic or sector-specific investment products.
Key Customers
- Individual investors seeking exposure to the genomics, immunology, and healthcare sectors.
- Institutional investors looking for thematic investment opportunities.
- Financial advisors seeking to diversify client portfolios.
- Investors interested in long-term growth potential in the healthcare industry.
Financials
Chart & Info
iShares Genomics Immunology and Healthcare ETF (IDNA) stock price: Price data unavailable
Latest News
No recent news available for IDNA.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IDNA.
Price Targets
Wall Street price target analysis for IDNA.
MoonshotScore
What does this score mean?
The MoonshotScore rates IDNA's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Common Questions About IDNA
What does iShares Genomics Immunology and Healthcare ETF do?
The iShares Genomics Immunology and Healthcare ETF (IDNA) is designed to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering. The ETF provides investors with targeted exposure to companies involved in genomic sequencing, immunotherapy development, and bioengineering technologies. By investing in a diversified portfolio of companies within these fields, IDNA aims to capture the potential upside from breakthroughs and advancements that could transform healthcare and improve patient outcomes.
What do analysts say about IDNA stock?
AI analysis is pending for IDNA. However, ETFs in the financial services sector are generally evaluated based on factors such as expense ratios, tracking error, diversification, and exposure to specific market segments. Investors may want to evaluate the ETF's investment objective, risk profile, and historical performance when making investment decisions. The ETF's focus on genomics, immunology, and healthcare may appeal to investors seeking exposure to high-growth areas within the healthcare industry. Further AI analysis will provide additional insights into the ETF's valuation and growth potential.
What are the main risks for IDNA?
The main risks for IDNA include regulatory hurdles, clinical trial failures, and competitive pressures from established pharmaceutical companies. The genomics, immunology, and bioengineering sectors are subject to strict regulatory oversight, and delays or unfavorable decisions could impact the performance of companies in the ETF's portfolio. Clinical trial failures can also negatively affect the value of biotechnology and pharmaceutical companies. Additionally, IDNA faces competition from other ETFs and investment vehicles offering exposure to the healthcare sector.
How is iShares Genomics Immunology and Healthcare ETF adapting to fintech disruption?
As an ETF, iShares Genomics Immunology and Healthcare ETF (IDNA) indirectly adapts to fintech disruption through the companies it holds within its portfolio. The ETF's success depends on the ability of its constituent companies to leverage fintech innovations to improve healthcare delivery, develop new therapies, and enhance patient outcomes. For example, companies involved in genomic sequencing and data analytics may utilize fintech solutions to accelerate research and development, personalize treatment plans, and improve the efficiency of healthcare systems. The ETF's performance will be influenced by the extent to which its holdings embrace and benefit from fintech advancements.
What regulatory challenges does iShares Genomics Immunology and Healthcare ETF face?
As an ETF, iShares Genomics Immunology and Healthcare ETF (IDNA) is subject to regulations governing investment companies and ETFs. These regulations include requirements for diversification, liquidity, and transparency. The ETF must also comply with securities laws and regulations related to trading and disclosure. Additionally, the companies held within the ETF's portfolio are subject to regulatory oversight from healthcare agencies, such as the FDA, which can impact their ability to develop and commercialize new products. Compliance with these regulations can be costly and time-consuming, and failure to comply could result in penalties or other adverse consequences.
What are the key factors to evaluate for IDNA?
iShares Genomics Immunology and Healthcare ETF (IDNA) currently holds an AI score of 47/100, indicating low score. Key strength: Exposure to high-growth sectors: genomics, immunology, and bioengineering.. Primary risk to monitor: Potential: Clinical trial failures and setbacks in drug development.. This is not financial advice.
How frequently does IDNA data refresh on this page?
IDNA prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven IDNA's recent stock price performance?
Recent price movement in iShares Genomics Immunology and Healthcare ETF (IDNA) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Exposure to high-growth sectors: genomics, immunology, and bioengineering.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The analysis is based on publicly available information and may be subject to change.
- AI analysis is pending for IDNA, which may provide additional insights.
- Investment decisions should be based on individual risk tolerance and financial circumstances.